
    
      Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA
      through the inhibition of the production/release of pro-inflammatory cytokines, such as
      IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.
    
  